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a b s t r a c t
Leishmaniasis is a major health problem in many parts of the world, caused by various species of Leish-
mania. Amastigotes are the clinically relevant form of the parasite in the human host and reside in
the parasitophorous vacuole within macrophages. Polymer–drug conjugates have been used for lysoso-
motropicdrugdeliveryandhavealreadyshownpotential inanticancerandantileishmanial chemotherapy.
We synthesised N-(2-hydroxypropyl)methacrylamide–amphotericin B (HPMA–AmB) copolymer con-
jugates in which the AmB was attached to the polymer through a degradable GlyPheLeuGly linker.
Antileishmanial activity was assessed in vitro against intracellular amastigotes in host macrophages
[murine peritoneal exudate macrophages (PEMs), murine bone marrow-derived macrophages (BMMs)
and differentiated THP-1 cells]. The most potent copolymers had 50% effective concentration (EC50) val-
ues of 0.03g/mL AmB equivalent against Leishmania donovani amastigotes in PEMs and BMMs and an
EC50 of 0.57g/mL AmB equivalent against L. donovani in THP-1 cells. This activity was comparable with
free AmB (EC50 =0.03–0.07g/mL against L. donovani in PEMs and BMMs and 0.24–0.42g/mL against
amastigotes in THP-1 cells) and Fungizone® (EC50 =0.04–0.07g/mL against amastigotes in PEMs). Con-
jugates also showed potent in vivo activity with ca. 50% inhibition of parasite burden at 1mg/kg body
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. Introduction
Leishmaniasis is a disease complex caused by obligate intracel-
ular protozoa of the genus Leishmania. The most serious form of
isease is the systemic infection visceral leishmaniasis (VL) (kala-
zar),which is fatal unless treated.Otherdiseasemanifestations are
utaneous leishmaniasis and mucocutaneous leishmaniasis, which
re severely debilitating and disﬁguring. There are an estimated
00000 new VL cases each year, with >90% of cases occurring in
ndia, Bangladesh, Nepal, Sudan, Brazil and Ethiopia [1,2]. Current
rst-line treatment for VL is focused on pentavalent antimoni-
ls (Pentostam® and Glucantime®), or conventional amphotericin
(amphotericin B deoxycholate; Fungizone®) in areas with high
ntimony treatment failure rates. Liposomal amphotericin B, mil-
efosine and paromomycin have become available in recent years
s alternative treatments [2].
Amphotericin B (AmB) is a polyene antibiotic, originally devel-
ped as a systemic antifungal, that is highly active against
∗ Corresponding author. Tel.: +44 1382 386 240; fax: +44 1382 386 373.
E-mail address: i.h.gilbert@dundee.ac.uk (I.H. Gilbert).
1 These two authors contributed equally to this work.
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Open accesand the International Society of Chemotherapy.
eishmania spp.However,major clinical drawbacksof treatment are
ts toxic side effects, the need for extensive monitoring and a com-
licateddosing regimen[2–4]. Lipid formulationsofAmBhavebeen
eveloped to improve tolerability and efﬁcacy and have been suc-
essfully applied in VL [3]. The liposomal formulation AmBisome®
as been shown to cure 90% of VL patients in India with single-
ose therapies of 5mg/kg and 7.5mg/kg [5,6]. However, high cost
as limited the wider use of AmBisome®, especially in low-income
ountrieswith thehighest burdenof disease, although theprice has
ecently been reduced for the public health sector in VL endemic
ountries [2,5,7].
The Leishmania parasite has a dimorphic life-cycle and within
he host resides as the amastigote stage in tissue macrophages
ithin a vacuole, called the parasitophorous vacuole (PV). The PV
as many similarities to late endosomes/lysosomes, for example
ow pH (ca. 5), many of the degradative enzymes associated with
ysosomes such as cathepsins B, D, H and L, as well as other pro-
eins typical of lysosomes and late endosomes such as lamp1 and
Open access under CC BY license.ab7p [8–10]. Thus, drug delivery systems for leishmaniasis that
mploy active and passive macrophage targeting strategies have
een investigated [11]. Polymer–drug conjugates have been used
or lysosomotropic drug delivery in the ﬁeld of anticancer therapy
12–15]. Cell entry is restricted to endocytosis, and polymer conju-
s under CC BY license.
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ates are subsequently trafﬁcked through endosomes to lysosomes
16]. By attaching a drug to the polymer via lysosomally degrad-
ble linkers, such as the GlyPheLeuGly (GFLG) linker, drugs can be
peciﬁcally released in lysosomes [12,17].
N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers have
hown promise in antileishmanial drug delivery of an 8-
minoquinoline [18,19]. HPMA is water soluble and non-
mmunogenic and has been in clinical trials in the cancer ﬁeld
14]. Other polymer–drug conjugates that showed potential in
ntileishmanial drug delivery include conjugates of antimonials
ith dextrin [20] and AmB with arabinogalactan [21–23].
We chose to study the delivery of AmB as a model drug
ased on its known efﬁcacy and toxicity. In this paper, we report
he synthesis and biological evaluation of HPMA-GFLG-AmB and
PMA-GFLG-AmB-mannosamine (ManN) conjugates as potential
ntileishmanial agents.
. Experimental design
.1. Materials, instruments and methods
Polymeric HPMA containing 9.03mol% GFLG linker activated
s the para-nitrophenol ester (ONp) (HPMA-GFLG-ONp) was pur-
hased from Polymer Laboratories Ltd. (Church Stretton, UK).
riethylamine was distilled from potassium hydroxide and stored
nder nitrogen. AmB with a content of amphotericin A <5% was
urchased from A.G. Scientiﬁc, Inc. (San Diego, CA). Other reagents
nd solvents were purchased from Aldrich and Fluka. All reactions
ere carried out at room temperature under an argon atmo-
phere.
Normal-phase thin-layer chromatography (TLC) was performed
n pre-coated sheets of silica 60F254, using methanol as the mobile
hase (Rf of AmB=0.31; Rf of ONp and of the polymer =0.9).
everse-phase TLC was carried out using pre-coated aluminium
heets reverse-phase 18F254s from Merck, using a mixture of
H2PO4 (0.025M, pH 5.0)–acetonitrile [9:1] as a mobile phase and
inhydrin as the stain (Rf of ManN=0.72; Rf of ONp and of the
olymer =0.9). SephadexTM LH-20 was purchased from Fisher Sci-
ntiﬁc.
Proton nuclear magnetic resonance (1H-NMR) spectra were
ecorded on a Bruker Avance DPX 500 spectrometer in CD3OD.
ll the signals are described as broad (br). UV-Vis spectra
ere recorded on a Beckman DU 640 spectrophotometer. Solid
hase extraction (SPE) high-performance liquid chromatogra-
hy (HPLC) analyses were performed using a Dionex UltiMate
000 HPLC instrument, using a Bondapack C18 10m 125Å,
00mm×4.6mm I.D. column (Waters). SPE was carried out using
ond Elut® C18 cartridges of 3mL capacity containing 100mg of
tationary phase (Varian).
.2. Synthesis of HPMA-GFLG-AmB conjugates (e.g. CIR1592)
A solution of AmB [251.4mg dissolved in 3.0mL of dimethyl
ulphoxide (DMSO), 0.26mmol] and triethylamine (38.0L,
.27mmol) were added to a stirred solution of HPMA-GFLG-ONp
277.4mg, 0.14mmol ONp) in dry DMSO (1.6mL), with monitor-
ng by normal-phase TLC. After 5h, more triethylamine (38.0L,
.27mmol)was added. The resultingmixturewas stirredovernight,
uenched with an excess of 1-amino-2-propanol (20.0L), precip-
tated with diethyl ether and centrifuged. The pellet was dissolved
n a minimum amount of methanol and puriﬁed by gel ﬁltration
sing LH-20 as stationary phase and methanol as eluent. The prod-
ct was a yellow foam, 191.0mg (yield based on polymer weight,
8.8%); ıH 1.03–5.99 (br, H of HPMA, glycine, leucine, phenylala-
b
o
c
wtimicrobial Agents 33 (2009) 441–448
ine and AmB); 6.31 (br, H of double bonds in AmB); 7.31 and 7.54
br, H of Ph in phenylalanine).
.3. Synthesis of HPMA-GFLG-ManN-AmB conjugate (CIR1669)
d-mannosamine hydrochloride (68.2mg dissolved in 5.0mL of
MSO) and triethylamine (43.0L) were stirred with a solution
f HPMA-GFLG-ONp (945.41mg, 0.47mmol ONp) in dry DMSO
5.0mL) for 4h, with monitoring by reverse-phase TLC. Then, AmB
415.0mg dissolved in 10.0mL of DMSO, 0.45mmol) and triethyl-
mine (61L, 0.44mmol) were added. The resulting solution was
tirred for5h,withmonitoringbynormal-phaseTLC.More triethyl-
mine (61.0L, 0.44mmol) was added, the mixture was stirred
vernight and quenched with an excess of 1-amino-2-propanol
70.0L). Further steps, as for CIR1592, gave the product CIR1669
s a yellow foam, 601mg (yield based on polymer weight, 63.6%);
H 1.03–5.99 (br, H of HPMA, glycine, leucine, phenylalanine, AmB
nd ManN); 6.36 (br, H of double bonds in AmB); 7.32 and 7.53 (br,
of Ph in phenylalanine).
.4. Synthesis of controls
HPMA-GFLG-COOH (CIR1465), HPMA-GFLG-1-amino-2-prop-
nol (HPMA-GFLG-AP) (CIR1466) and HPMA-GFLG-ManN
CIR1770) were prepared similarly by treating HPMA-GFLG-ONp
ith sodium hydroxide, 1-amino-2-propanol and d-mannosamine
ydrochloride, respectively.
.5. Determination of the ManN content in
PMA-GFLG-ManN-AmB by a modiﬁed Elson and Morgan method
18,19,24,25]
Samples (0.5mg) were hydrolysed with 6N HCl (ﬁnal volume
.0mL) at 60 ◦C for 5h and then dried under vacuum. The residue
as dissolved in 0.5mL of water and 0.5mL of acetyl acetone
eagent [4.8% (v/v) acetyl acetone in a buffer of 1.0M sodium bicar-
onate and1.0Msodiumcarbonate, pH9.6]. The resultingmixtures
ere stirred for 20min at 96 ◦C. Subsequently, the solutions were
ooled in ice and 2.5mL of absolute ethanol and 0.5mL of Ehrlich’s
eagent (0.8mgofp-dimethylaminobenzaldehyde in30mLof abso-
ute ethanol and30mLof concentratedHCl)were added and stirred
or 10min at 65 ◦C. Absorbance was measured at =530nm. A
alibration curve was obtained using mixtures of d-mannosamine
ydrochloride (17.6–58.7g/mL) andHPMA-GFLG-AP (0.5mg/mL).
.6. Determination of the total amphotericin B content in
PMA-GFLG-AmB and in HPMA-GFLG-ManN-AmB by UV-Vis
pectroscopy
A calibration curve was prepared using AmB in DMSO in the
ange1.1–10.3g/mLby recording theabsorbanceat416nm(maxi-
umabsorbance). Thiswas then used to calculate the total amount
f AmB associated with the polymer conjugates. HPMA copolymer
ontrol (CIR1465) in the same concentration range as the analysed
onjugate was used as blank.
.7. Determination of the free amphotericin B content in
PMA-GFLG-AmB and in HPMA-GFLG-ManN-AmB by SPE-HPLC
sing 1-amino-4-nitronaphthalene as internal standardC18 cartridges attached to aVac-Elut chamberwere conditioned
y passing 3mL of MeOH and 2mL of water later at a ﬂow rate
f 1mL/min. Methanolic sample solutions were loaded to the SPE
olumns at the ﬂow rate of 0.2mL/min and washed with 1mL of
ater at aﬂowrateof1mL/min toelute thecopolymer. The retained
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ree residual AmB and internal standard (IS) were eluted with 4mL
f MeOH. The methanolic solutions were dried under vacuum. The
btained residues were dissolved in 1.0mL of a mixture of ethylene
iamine tetra-acetic acid (EDTA) (20.0mM solution in water) and
cetonitrile (CH3CN) (60:40 v/v).
HPLC conditionswere: eluent EDTA (20.0mM inwater) and ace-
onitrile (60:40 v/v); a ﬂow rate of 1.0mL/min; retention time for
mB of 10.7min; retention time for the IS of 16.9min; injection
olume 100L; and detection at 405nm (maximum absorbance).
he calibration curve was obtained using mixtures of AmB
0.5–2.6g/mL), HPMA-GFLG-AP (0.2mg/mL) and IS (10g/mL)
y least-squares linear regression analysis. The peak area ratio of
mB to IS versus nominal concentration of the drug was plotted.
o impurities were detected during these analyses.
.8. In vitro antileishmanial activity against intracellular
mastigotesLeishmaniadonovani (MHOM/ET/67/L82)wasmaintained inSyr-
an hamsters and amastigoteswere harvested from the spleen of an
nfected animal. Murine peritoneal exudate macrophages (PEMs)
ere prepared as described previously [26]. THP-1 cells were dif-
1
B
T
c
c
ig. 1. Schematic representation of the synthesis of HPMA-GFLG-AmB and HPMA-GFLG
inker; AmB, amphotericin B; ManN, mannosamine.timicrobial Agents 33 (2009) 441–448 443
erentiated by incubation in medium containing 20ng/mL phorbol
2-myristate 13-acetate (PMA) (Sigma) for 2 days [27] and rested
n PMA-free medium overnight before infection. Bone marrow-
erived macrophages (BMMs) were harvested from BALB/C mice
ccording to a standard protocol with minor modiﬁcations [28].
ells were incubated in Dulbecco’s Modiﬁed Eagle’s Medium
DMEM) (Sigma) supplementedwith 10%heat-inactivated fetal calf
erum (hi-FCS) and 15% L929 cell supernatant at 37 ◦C in 5% CO2 in
umidiﬁed air for 8 days. Macrophages were harvested and plated
s above.
Adherent PEMs, BMMs and THP-1 cells were infected with L.
onovani amastigotes as described previously [26]. Stock solutions
f free AmB and HPMA-GFLG-AmB conjugates were prepared in
00% DMSO (Sigma) at 1mg/mL AmB equivalent. Fungizone® and
mBisome® were reconstituted according to the manufacturer’s
rotocol at stock concentrations of 5mg/mL and 4mg/mL AmB.
ubsequent dilutions were prepared in RPMI 1640 medium plus
0% hi-FCS. Maximum DMSO concentrations of 0.1% (PEMs and
MMs) and 0.5% (THP-1 cells) had no effect on parasite clearance.
wo hundred microlitres of three-fold serially diluted drug and
onjugate solutions were added to the respective wells and each
oncentration was tested in quadruplicate.
-ManN-AmB. HPMA, N-(2-hydroxypropyl)methacrylamide; GFLG, GlyPheLeuGly
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Infected cultures were incubated for 72h at 37 ◦C in a 5%
O2–95% humidiﬁed air mixture. At the experimental endpoint,
lideswere ﬁxedwith 100%methanol and stainedwith 10%Giemsa
n water. Drug and conjugate activity was determined from the
ercentage of infected macrophages in relation to a non-treated
ontrol upon microscopic counting of 100 macrophages per well.
ata were analysed by non-linear sigmoidal curve ﬁtting, and 50%
ffective concentration/90% effective concentration (EC50/EC90)
alues were estimated using Microsoft XLﬁt (ID Business Solu-
ion, Guildford, UK). Two to three separate experiments were
erformed.
.9. In vitro cytotoxicity testing
KB cells (HeLa contaminant, cervical adenocarcinoma-derived)
ere plated in 96-well plates (Becton Dickinson) at a density of
×104 cells/mL in RPMI 1640 medium+10% hi-FCS. Cells were
llowed to adhere overnight at 37 ◦C in 5% CO2 in humidiﬁed air.
or THP-1 cells, serial dilutions of drugs and conjugates were pre-
ared in 96-well plates and a suspension of THP-1 cells was added
t a seeding density of 5×105 cells/mL.
Stock solutions of HPMA-GFLG-AmB conjugates were prepared
t 20mg/mL AmB equivalent in 100% DMSO and subsequent three-
old serial dilutions in culture medium. Concentrations tested
anged from 200g/mL to 0.82g/mL AmB equivalent (maxi-
um DMSO concentration 1%) for KB cells and from 90g/mL
o 0.37g/mL AmB equivalent (maximum DMSO concentration
.45%) for THP-1 cells. Each concentration was tested in triplicate.
ultures were incubated for 72h at 37 ◦C in a 5% CO2–95% air mix-
ure. Twentymicrolitres of Alamar Blue® were added for the last 4h
KB) or 6h (THP-1) of incubation and plates were read on a Gem-
ni Spectrophotometer (Molecular Devices Ltd.), with excitation at
30nm and emission at 580nm.
Data were graphically expressed as percentage cell viability of
ontrol calculated as follows: (FI test agent dilution/FI untreated
ontrol)×100, where FI is the ﬂuorescence intensity emission unit.
.10. Statistical analysis
Statistical analysis was performed employing an unpaired, two-
ailed t-test assuming equal variance. A P-value of <0.05 was
onsidered statistically signiﬁcant.
.11. In vivo antileishmanial activityFemale BALB/c mice were infected by injection of 2×107
mastigotes/0.2mLofmedium into the tail vein andwere randomly
orted. Solutions of HPMA-GFLG-AmB conjugateswere prepared in
hosphate-buffered saline (Sigma). AmBisome® (Gilead Sciences)
as reconstituted according to the manufacturer’s protocol and
d
c
a
o
T
able 1
olymers prepared and evaluated.
ame Conjugate Total ManN (% w/w
HPMA-GFLG-ONp –
IR1592 HPMA-GFLG-AmB –
IR1668 HPMA-GFLG-AmB –
IR1669 HPMA-GFLG-ManN-AmB 5.9
IR1770 HPMA-GFLG-ManN 5.9
IR1465 HPMA-GFLG-COOH –
IR1466 HPMA-GFLG-AP
anN,mannosamine; AmB, amphotericin B;HPMA,N-(2-hydroxypropyl)methacrylamide
a The content of ManN in the conjugates CIR1669 and CIR1770 was determined by a mo
b The content of total Am B in the conjugates (CIR1592, CIR1668 and CIR1669) was dete
c Free residual AmB, reported as weight % of the total loaded drug, was determined bytimicrobial Agents 33 (2009) 441–448
ubsequent dilutions were prepared in 5% dextrose. Groups of ﬁve
icewere dosed intravenouslywith doses indicated belowonDays
, 9 and 11 post infection with a bolus injection of 0.2mL using a
5 gauge needle. Mice were monitored for any overt signs of toxic-
ty (e.g. hunched backs, piloerection, inactive behaviour) and group
eightswere recorded before and after treatment as a gross indica-
or of toxicity. OnDay14post infection,micewere euthanised, their
ivers were weighed and impression smears were taken. Smears
ere ﬁxed in 100% methanol, stained in 10% Giemsa in water and
he number of amastigotes per 500 host cell nuclei was counted.
eishman–Donovanunits (LDU)were calculated using the formula:
DU=number of parasites per host cell nucleus×organ weight in
g [29]. Deviations from the number of host cell nuclei given above
ere taken intoaccountandcorrected forbychanging the reference
ase.
The reduction in parasite burden achieved in a particular animal
as calculated relative to the mean LDU (n=5) of the control group
nd expressed as percentage inhibition. In dose–response exper-
ments, 50% and 90% effective dose (ED50 and ED90) values were
stimated using Microsoft XLﬁt as described above.
. Results
.1. Preparation of the polymer–drug conjugates
A library of HPMA-GFLG copolymer conjugates was prepared
ontaining AmB with or without mannose as a targeting moiety
Fig. 1; Table 1). The GFLG linker was chosen as it is known to be
leavedbycathepsinB [12,16,17],whichhasbeenshowntobe found
n the PV [8]. Theprepared conjugateswere puriﬁedby gel ﬁltration
using LH-20) to removeunreactedAmB. The free residual unbound
mB of the puriﬁed copolymers was <1% w/w of the total AmB
Table 1). Quantiﬁcation of mannose loading was carried out using
modiﬁed Elson and Morgan method [24,25].
.2. Evaluation of antileishmanial activity of polymer–drug
onjugates against intracellular Leishmania donovani amastigotes
nd cytotoxicity against mammalian cells
HPMA-GFLG-AmB conjugates were evaluated with respect to:
i) activities against intracellular amastigotes in different host
acrophages; (ii) inﬂuence of drug loading on antileishmanial
ctivity; (iii) inﬂuenceofmannosylationonantileishmanial activity
nd (iv) cytotoxicity against two mammalian cell lines.
Conjugates were biologically evaluated against intracellular L.
onovani amastigotes in PEMs, BMMs and differentiated THP-1
ells. Conjugates displayed activity of the same order of magnitude
s AmB and Fungizone® against intracellular Leishmania amastig-
tes (Table 2). Leishmania amastigotes residing in differentiated
HP-1 cells appeared less susceptible to AmB than amastigotes
)a Total AmB (% w/w)b Free AmB (% total drug)c
– –
27.5 <0.5
9.6 <0.1
10.4 <1.0
– –
– –
; GFLG, GlyPheLeuGly linker; ONp, para-nitrophenol ester; AP, 1-amino-2-propanol.
diﬁed Morgan and Elson method.
rmined by UV-Vis analysis.
high-performance liquid chromatography (HPLC) analysis.
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n primary macrophages (PEMs and BMMs), whether it was used
s the free compound, AmB deoxycholate (Fungizone®) or conju-
ated to polymers. At the EC50 level, this difference was 4–8-fold
or free AmB and Fungizone®. A higher difference was observed for
PMA-GFLG-AmB conjugates and this attained factors of 9–67-fold
n repeated experiments.
To assess the inﬂuence of drug loading, CIR1592 (27.5 wt% AmB)
as compared with CIR1668 (9.6wt% AmB). CIR1592 was more
otent against intracellular amastigotes in PEMs than the con-
ugate CIR1668, and this was statistically signiﬁcant in repeated
xperiments (P<0.05). However, there was no signiﬁcant differ-
nce between CIR1592 and CIR1668 against amastigotes in BMMs.
o clear picture emerged for amastigotes in differentiated THP-
cells, where in one experiment CIR1668 was more active than
IR1592 (P<0.05) and in a second experiment CIR1592 showed
igher activity than CIR1668 (data not shown).
To investigate the impact of mannosylation on antileishmanial
ctivity, we compared CIR1668 (9.6wt% AmB, no mannosyla-
ion) and CIR1669 (10.4wt% AmB, 5.9wt% ManN) in all three
eishmania–host cell models. Both conjugates displayed similar
ctivity, with no advantage of mannosylation observed (Table 2).
All conjugates displayed a favourable cytotoxicity proﬁle com-
ared with the free drug and Fungizone®, and comparable with
mBisome®. No toxicity was observed against KB cells up to
00g/mL AmB equivalent (Fig. 2a) or against monocytic THP-1
ells in suspension up to 90g/mL AmB equivalent (Fig. 2b). In
ontrast, Fungizone® and AmB started to show toxicity against KB
ells between 22.2g/mL and 66.7g/mL, AmB against THP-1 cells
etween 1.1g/mL and 3.3g/mL and Fungizone® against THP-1
ells at ca. 90g/mL.
.3. Evaluation of HPMA-GFLG-AmB and
PMA-GFLG-ManN-AmB in a mouse model of infection
Basedondemonstratedantileishmanial activityand lackof cyto-
oxicity in vitro, in vivo studies were conducted in BALB/c mice.
nitially, mice were dosed with conjugate CIR1592 (27.5% AmB)
t 3mg/kg and 1mg/kg body weight intravenously (i.v.)×3 and
mBisome® was included as comparator. CIR1592 showed excel-
ent activity at both doses and caused inhibition of parasite burden
f 99.6% at 3mg/kg i.v.×3 and 93.8% at 1mg/kg i.v.×3. For com-
arison, AmBisome® caused an inhibition of 99.9% at both doses
experiment 1, Table 3).
Based on this result, a dose–response experiment was per-
ormed comparing CIR1592 with AmBisome® at doses of 1, 0.3
nd 0.1mg/kg i.v.×3. Although AmBisome® remained more active,
ith an ED50 of 0.2mg/kg body weight, the experiment conﬁrmed
igh in vivo activity of CIR1592 with a predictive ED50 value of
a. 1mg/kg body weight (experiment 2, Table 3). There is a slight
ifference in the efﬁcacy of CIR1592 between experiment 1 and
xperiment 2; however, it should be noted that in experiment 1
evels of parasitaemia were approximately two-fold lower than in
xperiment 2.
To investigate the effect of the mannose targeting moiety on
arasite reduction in vivo, the antileishmanial activities of CIR1668
nd CIR1669 were compared in the BALB/c mouse model. CIR1668
nd CIR1669 conjugates suppressed hepatic parasite burden by
7.9% and 99.3% at 3mg/kg i.v.×3, respectively, and by 46.6% and
4.6%at 1mg/kg i.v.×3.No signiﬁcantdifference in antileishmanial
ctivity was found between the conjugate with and without man-
ose (experiment 3, Table 3). Importantly, no signs of toxicity in
ivowere recorded during administration of the HPMA-GFLG-AmB
onjugates at doses given, which is comparable with AmBisome®
Table 3).
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dig. 2. Cytotoxicity of amphotericin B (AmB), Fungizone and HPMA–AmB conjug
n suspension. Data are presented as % cell viability of control. Drug equivalent refe
n=3). HPMA, N-(2-hydroxypropyl)methacrylamide.
. Discussion
There is an urgent need to improve therapy for leishmaniasis.
xploring drugdelivery systems is oneway to circumvent problems
f drug toxicity and potentially to increase antileishmanial drug
fﬁcacy. We assessed the potential of HPMA–AmB drug conjugates
s antileishmanial agents in vitro and in vivo. AmB was chosen as it
s an important drug for the treatment of leishmaniasis but suffers
imitations. Conventional AmB in the form of a deoxycholate salt
Fungizone®) displays adverse reactions and requires administra-
ion under medical surveillance. A liposomal formulation of AmB
AmBisome®) has an improved safety proﬁle but its use has been
imited by cost. HPMA has shown potential in antileishmanial drug
elivery [18,19] andmuch information is available in the anticancer
eld [12,14].
On a cellular level, HPMA-GFLG-AmB conjugates showed potent
ctivity against intracellular L. donovani amastigotes in a panel of
acrophages in vitro and displayed decreased cytotoxicity against
a
b
n
a
able 3
ctivity of HPMA-GFLG-AmB conjugates in comparison with AmBisome® in BALB/c mice
olymer/drug Dose (mg/kg)×3a % inhibitionb
xperiment 1
IR1592 3 99.6 ± 0.1
1 93.8 ± 1.6
mBisome® 3 99.9 ± 0.1
1 99.9 ± 0.1
xperiment 2
IR1592 1 51.9 ± 7.7
0.3 13.0 ± 5.8
0.1 9.8 ± 9.3
mBisome® 1 98.7 ± 0.7
0.3 60.9 ± 5.9
0.1 22.8 ± 5.9
xperiment 3
IR1668 3 97.9 ± 1.0
1 46.6 ± 6.1
IR1669 3 99.3 ± 0.2
1 34.6 ± 9.4
PMA, N-(2-hydroxypropyl)methacrylamide; GFLG, GlyPheLeuGly linker; AmB, amphote
nits at experimental endpoint.
PMA copolymers were included as control at the top dose used. Parasite inhibition cau
ose of 3mg/kg body weight×3. No inhibition was observed at a dose of 1mg/kg body w
a Doses are given in mg/kg body weight and were administered on Days 7, 9 and 11 pos
b % inhibition and LDUs are given as arithmetic mean± standard error of the mean (n=IR1668, CIR1669 and CIR1592) against (a) KB cells (b) and monocytic THP-1 cells
AmB equivalent. Data represent the arithmetic mean± standard error of the mean
wo mammalian cell lines. There was some variability in activity
etween different batches of polymer conjugates, but there was
igniﬁcant activity against intracellular Leishmania in all batches
ested. We chose to study three different types of macrophages
ased on previous observations that different AmB formulations
isplayed different activities in the PEM and THP-1–amastigote
odels [30] as well as early studies that demonstrated differences
nmacrophagepopulations support of parasite growth. BMMswere
ound to bemore permissive than resident peritonealmacrophages
31] and represent natural host cells of Leishmania. Leishmania
mastigotes in different types of macrophages showed different
usceptibilities to AmB, whether given as the free drug, a lipo-
omal formulation or as the polymer conjugate. This difference
as particularly noticeable between primary macrophages (PEMs
nd BMMs) and a monocytic cell line (THP-1 cells) and might
e explained by differences in uptake and internalisation. Inter-
alisation of AmB has been shown to occur via endocytosis and
lso through uptake of AmB–low-density lipoprotein (LDL) com-
infected with Leishmania donovani.
ED50 (mg/kg) ED90 (mg/kg) LDUb
n.d. n.d. 590 ± 72
n.d. n.d. 590 ± 72
n.d. n.d. 590 ± 72
n.d. n.d. 590 ± 72
0.97 >1 1105 ± 141
1105 ± 141
1105 ± 141
0.22 0.77 1105 ± 141
1105 ± 141
1105 ± 141
n.d. n.d. 1249 ± 194
n.d. n.d. 1249 ± 194
n.d. n.d. 1249 ± 194
n.d. n.d. 1249 ± 194
ricin B; ED50/90, 50% and 90% effective dose, respectively; LDU, Leishman–Donovan
sed by CIR1465 and CIR1466 in experiment 1 was 42.2±5.4% and 35.1±7.7% at a
eight×3 in experiment 2.
t infection.
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lexes via the LDL receptor pathway [32–34]. Given the endocytic
oute of internalisation described for polymeric carriers, differ-
nces in endocytic/phagocytic potential of primary macrophages
nd macrophage-like THP-1 cells could be underlying reasons for
his observation.
Mannosylation has been used as an active targeting principle
n macrophage-speciﬁc drug delivery and experimental antileish-
anial chemotherapy [11,18,19,35,36], which prompted us to
nvestigate mannose as a targeting moiety on the HPMA-GFLG-
mB conjugates. However, we found no advantage of mannose
oadings at ca. 6%. The lack of a signiﬁcant difference in activity
etween the non-mannosylated and mannosylated conjugate may
e due to conformational hindrance that prevents interaction of
he polymer-bound mannose with the mannose receptor. Alter-
atively, the rate of uptake through other mechanism(s) may be
igniﬁcantly faster than that through mannose receptor-mediated
ndocytosis.
The most important ﬁndings are that (i) HPMA-GFLG-AmB con-
ugates showed potent antileishmanial activity in vivo, although
ess active than AmBisome® but of a similar order to it and (ii)
hat no signs of toxicity were recorded, even at the maximum
ose of 3mg/kg AmB equivalent used. It should be noted that this
ose is above the reported 50% lethal dose (LD50) of 2.5mg/kg for
ungizone® [37]. This clearly conﬁrms the improved toxicity proﬁle
f conjugates observed in vitro and demonstrates the same effect in
ivo. Itmeans that conjugates are less toxic but the reported ED50 is
etween 0.5mg/kg and 1mg/kg so the efﬁcacy is comparable. The
redictive ED50 for CIR1592 was ﬁve-fold higher than the ED50 of
mBisome®. However, it is known that AmBisome® is taken up by
acrophages of the reticuloendothelial system and preferentially
istributed to the liver and spleen,which are the target organsofVL,
nd that therapeutic doses remain for several weeks after loading
oses [38].
Further work is required to optimise these HPMA-GFLG-AmB
opolymer conjugates, including the investigation of mode of
ction, different linkers, biodistribution and pharmacokinetic data.
owever, the results presented here are a promising proof of prin-
iple for further studies in this area.
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